Shareholders will be ecstatic, with their stake up 20% over the past week following Bionano Genomics, Inc.'s (NASDAQ:BNGO) latest full-year results. The results don't look great, especially considering that statutory losses grew 10% toUS$88.13 per share. Revenues of US$30,776,000 did beat expectations by 6.9%, but it looks like a bit of a cold comfort. The analysts typically update their forecasts at each earnings report, and we can judge from their estimates whether their view of the company has changed or if there are any new concerns to be aware of. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

Following last week's earnings report, Bionano Genomics' twin analysts are forecasting 2025 revenues to be US$30.3m, approximately in line with the last 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 91% to US$6.00. Before this earnings announcement, the analysts had been modelling revenues of US$28.8m and losses of US$12.60 per share in 2025. There's been a pretty noticeable increase in sentiment, with the analysts upgrading revenues and making a very promising decrease in loss per share in particular.

Check out our latest analysis for Bionano Genomics

The consensus price target fell 93%, to US$4.00, suggesting that the analysts remain pessimistic on the company, despite the improved earnings and revenue outlook.

Of course, another way to look at these forecasts is to place them into context against the industry itself. These estimates imply that revenue is expected to slow, with a forecast annualised decline of 1.7% by the end of 2025. This indicates a significant reduction from annual growth of 30% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 5.8% per year. It's pretty clear that Bionano Genomics' revenues are expected to perform substantially worse than the wider industry.

The Bottom Line

The most important thing to take away is that the analysts reconfirmed their loss per share estimates for next year. Fortunately, they also upgraded their revenue estimates, although our data indicates it is expected to perform worse than the wider industry. The consensus price target fell measurably, with the analysts seemingly not reassured by the latest results, leading to a lower estimate of Bionano Genomics' future valuation.

With that said, the long-term trajectory of the company's earnings is a lot more important than next year. We have analyst estimates for Bionano Genomics going out as far as 2026, and you can see them free on our platform here.

However, before you get too enthused, we've discovered 4 warning signs for Bionano Genomics (3 don't sit too well with us!) that you should be aware of.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.